Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker MGX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | Laurence Reid Director | MGX Metagenomi Therapeutics, Inc. | Buy | 117 | $1.18 | $138 Buy | Form 4 ↗ |
| Sep 9, 2026 | Laurence Reid Director | MGX Metagenomi Therapeutics, Inc. | Buy | 19,883 | $1.17 | $23.3K Buy | Form 4 ↗ |
| Sep 8, 2026 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 358 | $1.16 | $415 Sale | Form 4 ↗ |
| Sep 8, 2026 | Jian Irish See Remarks, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 2,140 | $1.16 | $2,482 Sale | Form 4 ↗ |
| Sep 8, 2026 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,911 | $1.16 | $2,217 Sale | Form 4 ↗ |
| Jun 5, 2026 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 2,884 | $1.30 | $3,749 Sale | Form 4 ↗ |
| Jun 5, 2026 | Jian Irish See Remarks, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 3,737 | $1.30 | $4,858 Sale | Form 4 ↗ |
| Jun 5, 2026 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 558 | $1.30 | $725 Sale | Form 4 ↗ |
| Mar 5, 2026 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,581 | $1.60 | $2,530 Sale | Form 4 ↗ |
| Mar 5, 2026 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 482 | $1.60 | $771 Sale | Form 4 ↗ |
| Mar 5, 2026 | Jian Irish Chief Executive Officer, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 1,607 | $1.60 | $2,571 Sale | Form 4 ↗ |
| Dec 5, 2025 | Brian C. Thomas Director | MGX Metagenomi Therapeutics, Inc. | Sale | 3,830 | $1.77 | $6,779 Sale | Form 4 ↗ |
| Dec 5, 2025 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 199 | $1.77 | $352 Sale | Form 4 ↗ |
| Dec 5, 2025 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,576 | $1.77 | $2,790 Sale | Form 4 ↗ |
| Dec 5, 2025 | Jian Irish Chief Executive Officer, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 1,602 | $1.77 | $2,836 Sale | Form 4 ↗ |
| Sep 5, 2025 | Brian C. Thomas Director | MGX Metagenomi Therapeutics, Inc. | Sale | 2,701 | $1.81 | $4,889 Sale | Form 4 ↗ |
| Sep 5, 2025 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,576 | $1.81 | $2,853 Sale | Form 4 ↗ |
| Sep 5, 2025 | Jian Irish Chief Executive Officer, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 1,602 | $1.81 | $2,900 Sale | Form 4 ↗ |
| Sep 5, 2025 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 199 | $1.81 | $360 Sale | Form 4 ↗ |
| Jun 6, 2025 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 199 | $1.75 | $348 Sale | Form 4 ↗ |
| Jun 6, 2025 | Sarah B. Noonberg Chief Medical Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 5,239 | $1.75 | $9,168 Sale | Form 4 ↗ |
| Jun 6, 2025 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,576 | $1.75 | $2,758 Sale | Form 4 ↗ |
| Jun 6, 2025 | Brian C. Thomas Chief Executive Officer, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 10,785 | $1.75 | $18.9K Sale | Form 4 ↗ |
| Jun 6, 2025 | Jian Irish See Remarks, Director | MGX Metagenomi Therapeutics, Inc. | Sale | 6,390 | $1.75 | $11.2K Sale | Form 4 ↗ |
| Mar 5, 2025 | Matthew Wein See Remarks | MGX Metagenomi Therapeutics, Inc. | Sale | 930 | $1.87 | $1,739 Sale | Form 4 ↗ |
| Mar 5, 2025 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,808 | $1.87 | $3,381 Sale | Form 4 ↗ |
| Dec 5, 2024 | Pamela Wapnick Chief Financial Officer | MGX Metagenomi Therapeutics, Inc. | Sale | 1,559 | $1.86 | $2,900 Sale | Form 4 ↗ |
27 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:34 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances